Vector for cancer treatment
AssigneeCancer Research Technology Limited
InventorsLian Ni LEE, Senthil CHINNAKANNAN, Paul KLENERMAN
Life of this patent
Estimating the term…
Abstract
The present invention relates to an adenoviral vector or adeno-associated virus vector comprising a nucleotide sequence encoding a single cancer specific CD8+ T cell epitope, wherein the vector is capable of inducing an inflating memory CD8+ T cell response wherein said vector does not comprise a nucleic acid encoding further cancer specific T cell epitopes. It also relates to methods and uses of the vector.
Claims30
A method of inducing an inflating memory CD8+ T cell response comprising:
- administering a therapeutically effective amount of a pharmaceutical composition to a subject with a tumor, wherein the pharmaceutical composition comprises an adenoviral vector comprising a nucleotide sequence encoding a polypeptide comprising a single cancer-specific CD8+ T cell epitope, and wherein the adenoviral vector does not comprise a nucleic acid molecule encoding a cancer-specific T cell epitope other than the single cancer-specific CD8+ T cell epitope.
A method of treating cancer in a subject in need thereof, comprising:
- administering a therapeutically effective amount of a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises an adenoviral vector comprising a nucleotide sequence encoding a single cancer-specific CD8+ T cell epitope, and wherein the adenoviral vector does not comprise a nucleic acid molecule encoding a cancer-specific T cell epitope other than the single cancer-specific CD8+ T cell epitope.
An adenoviral vector comprising a nucleotide sequence encoding a single cancer-specific CD8+ T cell epitope, wherein the adenoviral vector does not comprise a nucleic acid molecule encoding a cancer-specific T cell epitope other than the single cancer-specific CD8+ T cell epitope, and wherein administration of the viral vector to a subject in need thereof induces an inflating memory CD8+ T cell response to the single cancer specific CD8+ T cell epitope in the subject.
A composition comprising:
- at least two adenoviral vectors, wherein each of the at least two adenoviral vectors comprises a nucleotide sequence encoding a polypeptide comprising a single cancer-specific CD8+ T cell epitope, wherein each of the at least two adenoviral vectors encodes a different single cancer-specific CD8+ T cell epitope, and wherein each of the at least two adenoviral vectors does not comprise a nucleic acid molecule encoding a cancer-specific T cell epitope other than the single cancer-specific CD8+ T cell epitope.
Dependencies are inferred from the claim text.